New Delhi, Dec 1 (NationPress) The escalating issue of obesity, a significant global health concern responsible for millions of preventable fatalities annually, is addressed in a recent report by the World Health Organization (WHO). The report, published on Monday, emphasizes that treatments such as Glucagon-Like Peptide-1 (GLP-1) medications cannot resolve the obesity crisis that affects over one billion individuals globally.

According to WHO, obesity is characterized by an adult Body Mass Index (BMI) of 30 or more.

WHO has sanctioned GLP-1 therapies for the management of obesity as a chronic, relapsing condition. These GLP-1 receptor agonists assist in lowering blood sugar levels, facilitating weight loss, diminishing the chances of heart and kidney issues, and even reducing the risk of premature mortality in type 2 diabetes patients.

However, the rising demand for GLP-1 therapies has led to the proliferation of counterfeit and substandard products, jeopardizing patient safety and eroding trust.

In response, WHO has introduced its inaugural guidelines on GLP-1 therapy usage, offering specific recommendations for three agents intended for the prolonged treatment of obesity in adults: liraglutide, semaglutide, and tirzepatide.

With these updated guidelines, the WHO has provided conditional recommendations for utilizing these therapies to assist individuals battling obesity in tackling this severe health issue as part of a holistic strategy that includes balanced diets, consistent physical activity, and support from healthcare professionals.

"Obesity is a pressing global health issue that WHO is dedicated to addressing by aiding nations and individuals worldwide in managing it effectively and equitably. Our latest guidance acknowledges that obesity is a chronic condition that necessitates thorough and ongoing care," stated WHO Director-General Dr. Tedros Adhanom Ghebreyesus.

"While medication alone is insufficient to resolve this global health emergency, GLP-1 therapies can assist millions in overcoming obesity and mitigating its associated risks," he added.

Obesity is a multifaceted, chronic illness and a significant contributor to noncommunicable diseases, including cardiovascular diseases, type 2 diabetes, and certain cancers. It also hampers recovery in patients with infectious diseases. Furthermore, the worldwide economic burden of obesity is anticipated to reach $3 trillion annually by 2030.

The newly established guidelines are expected to aid in curbing the soaring healthcare expenses related to managing obesity and its complications.

According to the latest WHO guidance, GLP-1 therapies may be administered to adults, excluding pregnant women, for the long-term management of obesity.

Patients using GLP-1 therapies should also receive intensive behavioral interventions, which encompass structured programs focusing on healthy eating and physical activity.

"Although GLP-1 therapies mark a significant advancement in treatment options for adults with obesity, the WHO guideline stresses that medications alone are not a panacea. Obesity is not just an individual problem; it is a societal challenge that necessitates a collaborative, multisectoral response," the report highlighted.

It advocates for the establishment of healthier environments through comprehensive population-level policies aimed at promoting health and preventing obesity; safeguarding individuals at high risk of developing obesity and its related comorbidities through targeted screening and structured early interventions; and ensuring access to lifelong, personalized care.

The guidelines also underline the essentiality of equitable access to GLP-1 therapies and the need for health systems to be prepared for the implementation of these medications. Without intentional policies, access to these therapies could worsen existing health disparities.

"Despite rapid production expansion, GLP-1 therapies are expected to reach fewer than 10 percent of those who could benefit by 2030. The guidelines urge the global community to explore strategies to enhance access, including pooled procurement, tiered pricing, and voluntary licensing, among others," the report stated.